Banco Votorantim S.A. Fixed-Rate Notes Rated 'B+' Aug 04

  • ID: 1833564
  • August 2004
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Aug. 24, 2004--Standard & Poor's Ratings Services said today that it assigned its 'B+' foreign-currency long-term credit rating to Banco Votorantim S.A. (Nassau Branch)'s $100 million fixed-rate notes (under its Euro MTN program), to be issued in the beginning of September 2004 and maturing in September 2007. The repayment of these notes will be in full at maturity. The local-currency credit ratings on the bank are 'BB/Stable/B' and the foreign-currency credit ratings are 'B+/Positive/B'. "The ratings on Banco Votorantim S.A. reflect the potential risks associated with the bank's treasury business and its exposure to sovereign risk through its securities portfolio, a common issue for Brazilian banks, and the risks associated with the economic environment in...

Companies mentioned in this report are: Banco Votorantim S.A.
Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Banco Votorantim S.A.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.